Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
Abstract
Ovarian cancer has long been known to be the deadliest cancer associated with the female reproductive system. More than 15% of ovarian cancer patients have a defective BRCA-mediated homologous recombination repair pathway that can be therapeutically targeted with PARP inhibitors (PARPi), such as Talazoparib (TLZ). The expansion of TLZ clinical approval beyond breast cancer has been hindered due to the highly potent systemic side effects resembling chemotherapeutics. Here we report the development of a novel TLZ-loaded PLGA implant (InCeT-TLZ) that sustainedly releases TLZ directly into the peritoneal (i.p.) cavity to treat patient-mimicking BRCA-mutated metastatic ovarian cancer (mOC).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 09, 2023
- Source ID
- 10.3389/fonc.2023.1175617
Entities
People
- Alexis Robinson
- Allen Green
- Bryanna Testino
- Daniela M. Dinulescu
- Merline Senat
- Needa Brown
- Shicheng Yang
- Srinivas Sridhar
Organizations
- Congressionally Directed Medical Research Programs
- National Institutes of Health